# Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia

> **NCT01251250** · PHASE1 · WITHDRAWN · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Refractory Chronic Lymphocytic Leukemia
- Stage II Chronic Lymphocytic Leukemia
- Stage III Chronic Lymphocytic Leukemia
- Stage IV Chronic Lymphocytic Leukemia

## Interventions

- **OTHER:** laboratory biomarker analysis
- **GENETIC:** western blotting
- **GENETIC:** gene expression analysis
- **OTHER:** pharmacological study
- **OTHER:** flow cytometry
- **GENETIC:** fluorescence in situ hybridization
- **BIOLOGICAL:** azadirachta indica
- **GENETIC:** reverse transcriptase-polymerase chain reaction

## Key facts

- **NCT ID:** NCT01251250
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-12
- **Primary completion:** 2011-07
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lost sponsor support
- **Last updated:** 2014-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251250, "Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01251250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*